Risankizumab + Placebo for risankizumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hidradenitis Suppurativa
Conditions
Hidradenitis Suppurativa
Trial Timeline
Jun 3, 2019 → Aug 2, 2021
NCT ID
NCT03926169About Risankizumab + Placebo for risankizumab
Risankizumab + Placebo for risankizumab is a phase 2 stage product being developed by AbbVie for Hidradenitis Suppurativa. The current trial status is completed. This product is registered under clinical trial identifier NCT03926169. Target conditions include Hidradenitis Suppurativa.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05969223 | Approved | Completed |
| NCT03926169 | Phase 2 | Completed |
| NCT03398135 | Phase 3 | Active |
| NCT03000075 | Phase 2 | Completed |
| NCT02719171 | Phase 2 | Completed |
Competing Products
20 competing products in Hidradenitis Suppurativa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab (M1095) + Adalimumab | MoonLake Immunotherapeutics | Phase 2 | 47 |
| Eltrekibart + Placebo | Eli Lilly | Phase 2 | 52 |
| Placebo + LY3041658 | Eli Lilly | Phase 2 | 52 |
| Placebo + Adalimumab | AbbVie | Approved | 85 |
| Lutikizumab + Placebo | AbbVie | Phase 3 | 77 |
| Adalimumab | AbbVie | Pre-clinical | 23 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 77 |
| adalimumab + placebo | AbbVie | Phase 3 | 77 |
| Lutikizumab | AbbVie | Phase 2 | 52 |
| adalimumab | AbbVie | Phase 3 | 77 |
| Lutikizumab + Placebo | AbbVie | Phase 2 | 52 |
| adalimumab | AbbVie | Phase 3 | 77 |
| adalimumab + placebo | AbbVie | Phase 3 | 77 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 52 |
| MEDI8968 + Saline | AstraZeneca | Phase 2 | 52 |
| Anifrolumab | AstraZeneca | Phase 2 | 52 |